Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic, observational, and trial evidence
PubMed 23770180 · doi:10.1016/j.jacc.2013.05.045
What was done
This narrative review summarizes clinical and experimental evidence on the relationship between obstructive sleep apnea (OSA), obesity, and metabolic syndrome. It synthesizes findings from animal models of intermittent hypoxia, human observational cohort studies, and intervention trials evaluating continuous positive airway pressure (CPAP).
What was found
The review notes that moderate-to-severe OSA affects approximately 60% of patients with metabolic syndrome. OSA is reported to be independently associated with increased sympathetic activation, systemic inflammation, endothelial dysfunction, arterial stiffness, atherosclerosis, glucose levels, and triglyceride levels. A cited 3-month randomized controlled crossover trial demonstrated that CPAP treatment significantly decreased blood pressure, triglyceride levels, and visceral fat. Cohort studies consistently demonstrate an association between OSA and increased cardiovascular mortality independent of obesity. Specific numeric effect estimates and confidence intervals for these associations were not provided in the abstract beyond the ~60% prevalence figure.
Why it matters
It emphasizes that OSA is an active, independent driver of cardiometabolic dysfunction rather than a mere epiphenomenon of obesity, highlighting CPAP as a potential therapeutic target to reduce cardiovascular risk.
Limits
The paper is a narrative review without systematic search criteria, quantitative meta-analysis, or risk-of-bias assessment. Specific study populations, sample sizes, and detailed quantitative effect sizes for the cited primary studies are not reported in the abstract.
Cited by
- context Insulin resistance is mechanistically linked to sleep apnea by promoting fat deposition in the pharynx and upper airway.